The role of the renin-angiotensin system in aortic aneurysmal diseases. 2008

Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
Graduate Center for Nutritional Sciences, Wethington Building, Room 521b, 900 South Limestone Street, University of Kentucky, Lexington, KY 40536-0200, USA.

The renin-angiotensin system has been invoked in the development of both abdominal and thoracic aortic aneurysms. This has been demonstrated experimentally by the chronic subcutaneous infusion of angiotensin II, which consistently leads to development of abdominal aortic aneurysms (AAAs) in mice. Angiotensin II-induced AAAs have highly heterogenous cellular and extracellular matrix characteristics throughout the aorta that change markedly with infusion duration. The mechanistic basis for the reproducible location of AAA development has not been elucidated, but many insights have been provided, especially regarding receptor and inflammatory mechanisms. A recent clinical study provided limited evidence for extrapolating these results to mechanisms of human AAAs. Experimental evidence has also demonstrated that antagonism of angiotensin II type 1 (AT1) receptors prevents ascending aortic aneurysms in a murine model of Marfan's syndrome. A clinical study is currently ongoing to demonstrate the efficacy of AT1 receptor antagonism in humans.

UI MeSH Term Description Entries
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D017544 Aortic Aneurysm, Abdominal An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm. Abdominal Aorta Aneurysm,Aneurysm, Abdominal Aorta,Abdominal Aortic Aneurysm,Aneurysm, Abdominal Aortic,Abdominal Aorta Aneurysms,Abdominal Aortic Aneurysms,Aorta Aneurysm, Abdominal
D017545 Aortic Aneurysm, Thoracic An abnormal balloon- or sac-like dilatation in the wall of the THORACIC AORTA. This proximal descending portion of aorta gives rise to the visceral and the parietal branches above the aortic hiatus at the diaphragm. Aneurysm, Thoracic Aorta,Thoracic Aorta Aneurysm,Thoracic Aortic Aneurysm,Aneurysm, Thoracic Aortic,Aorta Aneurysm, Thoracic,Thoracic Aorta Aneurysms,Thoracic Aortic Aneurysms
D047228 Angiotensin II Type 1 Receptor Blockers Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. Angiotensin II Type 1 Receptor Antagonist,Angiotensin II Type 1 Receptor Blocker,Sartan,Angiotensin 2 Type 1 Receptor Antagonists,Angiotensin II Type 1 Receptor Antagonists,Sartans,Selective Angiotensin II Receptor Antagonists,Type 1 Angiotensin Receptor Antagonists,Type 1 Angiotensin Receptor Blockers
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
November 2017, Protein and peptide letters,
Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
September 1996, Puerto Rico health sciences journal,
Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
December 2013, European journal of clinical investigation,
Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
September 2018, Hypertension (Dallas, Tex. : 1979),
Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
May 1997, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
December 2001, Hypertension (Dallas, Tex. : 1979),
Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
July 1998, Medizinische Klinik (Munich, Germany : 1983),
Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
July 2011, Pharmacology & therapeutics,
Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
January 2013, Seminars in nephrology,
Hong Lu, and Debra L Rateri, and Lisa A Cassis, and Alan Daugherty
April 1974, Zeitschrift fur Allgemeinmedizin,
Copied contents to your clipboard!